Mumbai, Maharashtra, India, April 2025 — Shaik Barak Tulla has been appointed as Senior Vice President at SUN PHARMA, bringing with him over 25 years of distinguished leadership in the pharmaceutical industry. Known for his transformative leadership style and growth-oriented strategies, Shaik’s appointment is a strategic step by Sun Pharma as it continues to strengthen its senior leadership bench in a competitive global market.
Prior to joining Sun Pharma, Shaik served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla, where he played a pivotal role in enhancing profitability and solidifying Cipla’s leadership in respiratory, anti-infective, and critical care segments. His efforts led to the successful stewardship of marquee brands like Foracort, Azee, and Mucinac, while leading large-scale commercial transformations and digital initiatives such as Berok Zindagi.
Throughout his time at Cipla, Shaik demonstrated excellence in building high-impact teams, integrating AI-driven commercial planning, and championing Sales Force Effectiveness (SFE). His strategic focus on people-first leadership enabled one of the industry’s lowest attrition rates and consistently high achiever performance.
Over the years, Shaik held progressively senior roles within Cipla, including Cluster Lead – Nebulization Respiratory, where he scaled revenues from ₹40 Cr to ₹500 Cr, and Head – Sales and Marketing Critical Care, where he led key institutional launches and engagement programs. A certified executive alumnus of ISB, INSEAD, IIM Ahmedabad, and Singapore Management University, Shaik brings deep domain expertise and visionary leadership to Sun Pharma’s global commercial strategy.
At Sun Pharma, Shaik will be responsible for spearheading commercial innovation, scaling operations, and accelerating business performance across key markets and portfolios. His appointment reflects Sun Pharma’s unwavering commitment to excellence, innovation, and its mission to provide high-quality, affordable medicines across the globe.
Sun Pharma is the world’s fourth-largest speciality generic pharmaceutical company and the No. 1 pharmaceutical company in India. With a presence in over 100 countries, Sun Pharma is trusted for its high-quality, affordable medicines. Its global operations span more than 40 manufacturing facilities across five continents, supported by advanced R&D centres and a multicultural workforce of over 50 nationalities.
Powered by a team of around 3,000 scientists, Sun Pharma continuously invests 6–8% of annual revenues in R&D. The company’s robust culture of innovation and collective growth is encapsulated in its Employee Value Proposition, “Create Your Own Sunshine,” driven by the pillars of Better Every Day, Take Charge, and Thrive Together. This philosophy empowers every employee to unlock their potential and contribute to the company’s enduring success in global healthcare.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
